Preclinical and clinical data demonstrated PD-1/L1 immune checkpoint as a relevant target for immunotherapy in HPV+ cancers, based on the prominent role of PD-1 and PD-L1 in HPV-driven immune evasion. The gene discussed is PDCD1; the disease is cancer.